Shots:
- BMS has reported the P-III (EXCALIBER-RRMM) trial data assessing iberdomide + daratumumab + dexamethasone (IberDd) vs daratumumab + bortezomib + dexamethasone (DVd) in pts with r/r multiple myeloma
- The trial has 2 stages: Stage 1 randomized ~200 pts to iberdomide (1, 1.3, or 1.6mg) plus daratumumab & dexamethasone, identifying 1mg as the selected dose; Stage 2 randomized ~664 pts to IberDd or DVd
- Trial showed improvement in MRD negativity rates in the interim analysis, & per DMC recommendation will continue unchanged to assess other dual-1EP of PFS as well as 2EPs of OS, & safety; data to be discussed with global health authority
Ref: BMS | Image: BMS| Press Release
Related News:- BMS Reports the US FDA’s sBLA Acceptance and Priority Review of Breyanzi for R/R Marginal Zone Lymphoma (MZL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
